May 15, 2019
An all-important reimbursement policy panel on May 15 approved the listing of Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) on May 22, with a NHI price tag of some 33.5 million yen. It will be subject to review under Japan’s...read more